Nicola Camisassi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nicola Camisassi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Conti
Department of Urology, European Institute of Oncology (IEO) IRCCS, 20141 Milan, Italy
1 shared publication Daniele Maiettini
European Inst Oncol IRCCS, IEO, Div Intervent Radiol, I-20141 Milan, Italy
1 shared publication- Daniele Maiettini
Division of Interventional Radiology, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
1 shared publication - Francesco Alessandro Mistretta
Department of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122, Milan, Italy
1 shared publication Franco Orsi
European Inst Oncol IRCCS, IEO, Div Intervent Radiol, I-20141 Milan, Italy
1 shared publication- Franco Orsi
Division of Interventional Radiology, IRCCS Istituto Europeo di Oncologia (IEO), Via Giuseppe Ripamonti 435, 20141, Milan, Italy.
1 shared publication
Latest Publications
- Open Access
- 13 July 2020
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 14, 1070
Local recurrence of renal cell carcinoma successfully treated with fusion imaging-guided percutaneous thermal ablation
Image-guided thermal ablations are increasingly applied in the treatment of renal cancers, under the guidance of ultrasound (US) or computed tomography (CT). Fusion imaging allows exploitation of the strengths of all imaging modalities simultaneously, eliminating or minimising the weaknesses of every single modality. We present a case of a 68-year-old patient treated using US/CT fusion imaging to guide radiofrequency ablation for local recurrence of renal cell carcinoma undetectable by ultrasound.
- 13 July 2020
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 14, 1070
Open AccessLocal recurrence of renal cell carcinoma successfully treated with fusion imaging-guided percutaneous thermal ablation
Image-guided thermal ablations are increasingly applied in the treatment of renal cancers, under the guidance of ultrasound (US) or computed tomography (CT). Fusion imaging allows exploitation of the strengths of all imaging modalities simultaneously, eliminating or minimising the weaknesses of every single modality. We present a case of a 68-year-old patient treated using US/CT fusion imaging to guide radiofrequency ablation for local recurrence of renal cell carcinoma undetectable by ultrasound.
- Open Access
Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center
Image-guided thermal ablations are increasingly applied in the treatment of renal cancers, under the guidance of ultrasound (US) or computed tomography (CT). Sometimes, multiple ablations are needed. The aim of the present study was to evaluate the long-term results in patients with renal mass treated with radiofrequency ablation (RFA) with both US and CT, with a focus on the multiple ablations rate. 149 patients (median age 67 years) underwent RFA from January 2008 to June 2015. Median tumor diameter was 25 mm (IQR 17–32 mm). Median follow-up was 54 months (IQR 44–68). 27 (18.1%) patients received multiple successful ablations, due to incomplete ablation (10 patients), local tumor progression (8 patients), distant tumor progression (4 patients) or multiple tumor foci (5 patients), with a primary and secondary technical efficacy of 100%. Complications occurred in 13 (8.7%) patients (6 grade A, 5 grade C, 2 grade D). 24 patients died during follow-up, all for causes unrelated to renal cancer. In conclusion, thermal ablations with the guidance of US and CT are safe and effective in the treatment of renal tumors in the long-term period, with a low rate of patients requiring multiple treatments over the course of their disease.
Open AccessLong-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center
Image-guided thermal ablations are increasingly applied in the treatment of renal cancers, under the guidance of ultrasound (US) or computed tomography (CT). Sometimes, multiple ablations are needed. The aim of the present study was to evaluate the long-term results in patients with renal mass treated with radiofrequency ablation (RFA) with both US and CT, with a focus on the multiple ablations rate. 149 patients (median age 67 years) underwent RFA from January 2008 to June 2015. Median tumor diameter was 25 mm (IQR 17–32 mm). Median follow-up was 54 months (IQR 44–68). 27 (18.1%) patients received multiple successful ablations, due to incomplete ablation (10 patients), local tumor progression (8 patients), distant tumor progression (4 patients) or multiple tumor foci (5 patients), with a primary and secondary technical efficacy of 100%. Complications occurred in 13 (8.7%) patients (6 grade A, 5 grade C, 2 grade D). 24 patients died during follow-up, all for causes unrelated to renal cancer. In conclusion, thermal ablations with the guidance of US and CT are safe and effective in the treatment of renal tumors in the long-term period, with a low rate of patients requiring multiple treatments over the course of their disease.